Show simple item record

2018-11-15Zeitschriftenartikel DOI: 10.25646/6043
Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia
dc.contributor.authorNy, Sofia
dc.contributor.authorEdquist, Petra
dc.contributor.authorDumpis, Uga
dc.contributor.authorGröndahl-Yli-Hannuksela, Kirsi
dc.contributor.authorHermes, Julia
dc.contributor.authorKling, Anna-Maria
dc.contributor.authorKlingeberg, Anja
dc.contributor.authorKozlov, Roman
dc.contributor.authorKällman, Owe
dc.contributor.authorLis, Danuta O.
dc.contributor.authorPomorska-Wesołowska, Monika
dc.contributor.authorSaule, Mära
dc.contributor.authorTegmark Wisell, Karin
dc.contributor.authorVuopio, Jaana
dc.contributor.authorPalagin, Ivan
dc.contributor.authorNoDARS UTIStudy Group
dc.date.accessioned2019-03-29T13:14:16Z
dc.date.available2019-03-29T13:14:16Z
dc.date.issued2018-11-15none
dc.identifier.other10.1016/j.jgar.2018.11.004
dc.identifier.urihttp://edoc.rki.de/176904/6078
dc.description.abstractObjectives In the Northern Dimension Antibiotic Resistance Study (NoDARS), Finland, Germany, Latvia, Poland, Russia and Sweden collected urine samples from outpatient women (aged 18–65 years) with symptoms of uncomplicated urinary tract infection (UTI) to investigate the levels of antimicrobial resistance (AMR) among Escherichia coli isolates. Methods A total of 775 E. coli isolates from 1280 clinical urine samples were collected from October 2015 to January 2017. Antimicrobial susceptibility testing was performed and the results were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Results Overall AMR rates to the commonly used antibiotics nitrofurantoin, fosfomycin and mecillinam (except for Germany that was missing a result for mecillinam) were 1.2%, 1.3% and 4.1%, respectively. The highest overall resistance rates were determined for ampicillin (39.6%), trimethoprim (23.8%), trimethoprim/sulfamethoxazole (22.4%), amoxicillin/clavulanic acid (16.7%) and ciprofloxacin (15.1%), varying significantly between countries. The rate of extended-spectrum β-lactamase (ESBL) production was 8.7%. None of the isolates showed resistance to meropenem. Conclusions In most cases, low AMR rates were detected against the first-line antibiotics recommended in national UTI treatment guidelines, giving support to their future use. These results also support the European Association of Urology guidelines stating that nitrofurantoin, fosfomycin and mecillinam are viable treatment options for uncomplicated UTI.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectOutpatient UTIeng
dc.subjectEscherichia colieng
dc.subjectAntimicrobial resistanceeng
dc.subjectRisk factorseng
dc.subjectTreatment recommendationseng
dc.subjectWestern and Eastern Europeeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleAntimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russianone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6078-5
dc.identifier.doihttp://dx.doi.org/10.25646/6043
dc.type.versionpublishedVersionnone
local.edoc.container-titleJournal of Global Antimicrobial Resistancenone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.sciencedirect.com/science/article/pii/S2213716518302200#!none
local.edoc.container-publisher-nameElseviernone
local.edoc.container-volume17none
local.edoc.container-issueJune 2019none
local.edoc.container-reportyear2018none
local.edoc.container-year2018none
local.edoc.container-firstpage25none
local.edoc.container-lastpage34none
local.edoc.rki-departmentInfektionsepidemiologienone
dc.description.versionPeer Reviewednone

Show simple item record